205 related articles for article (PubMed ID: 18279794)
1. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs.
Davda JP; Jain M; Batra SK; Gwilt PR; Robinson DH
Int Immunopharmacol; 2008 Mar; 8(3):401-13. PubMed ID: 18279794
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
3. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.
Wittel UA; Jain M; Goel A; Chauhan SC; Colcher D; Batra SK
Nucl Med Biol; 2005 Feb; 32(2):157-64. PubMed ID: 15721761
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.
Goel A; Colcher D; Baranowska-Kortylewicz J; Augustine S; Booth BJ; Pavlinkova G; Batra SK
Cancer Res; 2000 Dec; 60(24):6964-71. PubMed ID: 11156397
[TBL] [Abstract][Full Text] [Related]
5. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.
Goel A; Beresford GW; Colcher D; Pavlinkova G; Booth BJ; Baranowska-Kortylewicz J; Batra SK
J Biochem; 2000 May; 127(5):829-36. PubMed ID: 10788792
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
[TBL] [Abstract][Full Text] [Related]
7. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors.
Jain M; Chauhan SC; Singh AP; Venkatraman G; Colcher D; Batra SK
Cancer Res; 2005 Sep; 65(17):7840-6. PubMed ID: 16140953
[TBL] [Abstract][Full Text] [Related]
8. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments.
Ferl GZ; Kenanova V; Wu AM; DiStefano JJ
Mol Cancer Ther; 2006 Jun; 5(6):1550-8. PubMed ID: 16818514
[TBL] [Abstract][Full Text] [Related]
9. Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting.
Pavlinkova G; Batra SK; Colcher D; Booth BJ; Baranowska-Kortylewicz J
Peptides; 2003 Mar; 24(3):353-62. PubMed ID: 12732332
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
13. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
14. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody.
Beresford GW; Pavlinkova G; Booth BJ; Batra SK; Colcher D
Int J Cancer; 1999 Jun; 81(6):911-7. PubMed ID: 10362138
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.
Baxter LT; Zhu H; Mackensen DG; Jain RK
Cancer Res; 1994 Mar; 54(6):1517-28. PubMed ID: 8137258
[TBL] [Abstract][Full Text] [Related]
16. Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.
Goel A; Augustine S; Baranowska-Kortylewicz J; Colcher D; Booth BJ; Pavlinkova G; Tempero M; Batra SK
Clin Cancer Res; 2001 Jan; 7(1):175-84. PubMed ID: 11205906
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
